Newborn Screening Tests: What They Check For

Newborn screening is a mandatory public health program that tests infants — typically within the first 24 to 48 hours of life — for a defined set of serious medical conditions that show no outward symptoms at birth. Early detection through these tests allows treatment to begin before irreversible damage occurs. The regulatory and programmatic framework for pediatric care that governs these tests is shaped by federal guidance and state-level implementation requirements.

Definition and Scope

Newborn screening encompasses three distinct testing modalities: dried blood spot (DBS) biochemical analysis, pulse oximetry, and hearing evaluation. Together, these form what the Health Resources and Services Administration (HRSA) calls the Recommended Uniform Screening Panel (RUSP) — a federal advisory list that, as of the most recent revision, includes 37 core conditions and 26 secondary conditions.

Conditions on the RUSP are selected using criteria established by the Secretary of Health and Human Services' Advisory Committee on Heritable Disorders in Newborns and Children (ACHDNC). A condition must satisfy evidence thresholds related to natural history, screening test validity, and the existence of proven treatment before nomination to the core panel. State health departments retain legal authority over which conditions are included in their individual programs; as of 2024, state panels range from screening for fewer than 30 to more than 50 conditions, depending on the state (HRSA RUSP).

The broader landscape of pediatric preventive care — including well-child visits and developmental checkups — connects to newborn screening as the starting point for longitudinal health monitoring that extends through adolescence.

How It Works

Newborn screening follows a structured sequence with four discrete phases:

  1. Specimen collection — A heel-stick blood sample is collected from the newborn, ideally between 24 and 48 hours after birth. Blood drops are absorbed onto standardized filter paper cards, which are then dried and shipped to a state public health laboratory.
  2. Laboratory analysis — Tandem mass spectrometry (MS/MS) is the primary analytical platform for metabolic disorders. MS/MS can screen for more than 40 conditions from a single blood spot by measuring the mass-to-charge ratios of metabolites including amino acids, acylcarnitines, and fatty acids. Additional enzymatic and molecular assays supplement MS/MS for conditions such as lysosomal storage disorders and severe combined immunodeficiency (SCID).
  3. Pulse oximetry screening — Conducted separately from the blood spot, this test screens for critical congenital heart disease (CCHD). A pulse oximeter probe is placed on the right hand and one foot; a combined oxygen saturation reading below 95% or a difference greater than 3% between the two sites triggers follow-up evaluation (CDC CCHD Screening).
  4. Hearing screening — Either automated auditory brainstem response (AABR) or otoacoustic emissions (OAE) testing is performed before hospital discharge. The Joint Committee on Infant Hearing (JCIH) 2019 position statement sets the benchmark: all infants should be screened by 1 month of age, with confirmed hearing loss diagnosed by 3 months and intervention begun by 6 months — a sequence known as the 1-3-6 guideline.

Common Scenarios

Metabolic disorders form the largest category on the RUSP. Phenylketonuria (PKU) was the first condition to be universally screened (Dr. Robert Guthrie's method was adopted nationally in the 1960s), and it remains a reference-case example: without dietary phenylalanine restriction starting in the first weeks of life, PKU causes severe intellectual disability. The condition affects approximately 1 in 10,000 to 15,000 newborns in the United States (NIH MedlinePlus on PKU).

Endocrine disorders, particularly congenital hypothyroidism (CH) and congenital adrenal hyperplasia (CAH), represent the highest-prevalence conditions on the panel. CH occurs in approximately 1 in 2,000 to 4,000 newborns and is treatable with thyroid hormone replacement; untreated CH is the leading preventable cause of intellectual disability worldwide (American Academy of Pediatrics, AAP).

Hemoglobin disorders — including sickle cell disease (SCD) — are screened via high-performance liquid chromatography (HPLC) or isoelectric focusing. Sickle cell disease affects approximately 1 in 365 Black or African American newborns in the United States (CDC Sickle Cell Disease Facts), and early identification allows prophylactic penicillin and pneumococcal vaccination protocols to begin before the first episode of sepsis.

Immunologic conditions, most notably SCID, were added to the RUSP in 2010. SCID screening relies on T-cell receptor excision circles (TRECs), DNA biomarkers detectable in dried blood spots. Without hematopoietic stem cell transplantation, infants with SCID rarely survive beyond their first year.

Decision Boundaries

Not all abnormal screening results indicate disease. Newborn screening is designed as a population-level risk-stratification tool, not a diagnostic test; false positives are expected and built into program design to maximize sensitivity. A positive screen triggers a mandatory diagnostic workup — it does not constitute a diagnosis.

Screen-positive vs. diagnostic positive: A dried blood spot result above the laboratory's cutoff value for, say, medium-chain acyl-CoA dehydrogenase deficiency (MCADD) must be confirmed by plasma acylcarnitine profile, urine organic acids, and molecular testing before a clinical diagnosis is established.

Second-tier testing: For conditions with high false-positive rates — such as cystic fibrosis screening via immunoreactive trypsinogen (IRT) — second-tier molecular testing for CFTR mutations is performed reflexively on the same dried blood spot before results are reported to providers, reducing unnecessary follow-up.

Timing effects: Specimens collected before 24 hours of age have higher false-positive and false-negative rates for conditions like PKU and galactosemia due to insufficient metabolite accumulation. The broader index of pediatric diagnostic resources contextualizes how this timing sensitivity intersects with early hospital discharge protocols.

Conditions not on all state panels: Krabbe disease, for example, is on the RUSP secondary panel but is actively screened only in a subset of states. Families with a family history of a condition not covered by their state's panel may access supplemental private newborn screening through laboratories offering expanded panels, though such testing falls outside the public health program structure.

Genetic confirmation, specialist referral timelines, and long-term monitoring protocols are addressed through programs such as the Newborn Screening Translational Research Network (NBSTRN), which coordinates follow-up data collection across participating state programs.

References

The law belongs to the people. Georgia v. Public.Resource.Org, 590 U.S. (2020)